News

After encouraging early data were released, the FDA granted breakthrough therapy designation to olomorasib, an oral KRAS G12C inhibitor, for the treatment of previously treated advanced pancreatic cancer.

FDA tentatively OKs cabozantinib capsules for renal cell carcinoma, hepatocellular carcinoma, and epNETs, with dose-conversion guidance, error warning, and improved absorption.

Damon R. Reed, MD, compared the carefully considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.

Phase 3 Asian trial shows acalabrutinib sharply improves progression-free survival vs chlorambucil-rituximab in untreated, medically unfit CLL patients with favorable safety.

Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Patients favor subcutaneous pembrolizumab for faster visits and comparable safety, signaling a convenient new option across solid tumors.

Erika Hamilton, MD, discusses HER2CLIMB-05 data showing tucatinib plus HP maintenance extends PFS in HER2+ breast cancer, including brain metastases.

The FDA expanded the use of the radioligand therapy to the hormone-sensitive setting in metastatic prostate cancer.

"Although I am disappointed that the PFS improvement was not statistically significant, I look forward to continuing to follow these results," Robert Coleman, MD.

FDA orphan designation boosts enzomenib for ALL, as menin inhibitor trials show early responses and tolerable safety in relapsed leukemia.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

The July 2026 oncology roundup spotlights rapid cancer drug approvals, new dosing options, a melanoma virus therapy vote, and key rejections shaping treatment trends.

FDA advisers back RP1 plus nivolumab for anti–PD-1–refractory advanced melanoma, citing durable responses despite design concerns and awaiting confirmatory IGNYTE-3 data.

The sBLA for subcutaneous amivantamab is supported by results from the phase 1b/2 OrigAMI-4 study.

FDA grants designations to off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

Digital app-based therapy helps breast cancer survivors reduce anxiety over 12 months; however, depression gains lagged.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

Phase 3 results show intravesical cretostimogene drives durable complete responses and bladder preservation in BCG-unresponsive NMIBC.

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

SimpleScreen CRC has demonstrated a sensitivity of 81.1% for CRC detection.

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.